AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2913129 — intervention group
Group type: EXPERIMENTAL
Intervention: MC immunotherapy
Number of subjects: 14
Study 2913129 — intervention group
Group type: COMPARATOR
Intervention: Placebo immunotherapy
Number of subjects: 14
Study 328108 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 40 microgram
Number of subjects: 0
Study 328108 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 0
Study 31540867 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 1·0 mg once weekly
Number of subjects: 788
Study 31540867 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin 300 mg once daily
Number of subjects: 788
Study 29065390 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted treatment
Number of subjects: 227
Study 25751232 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (partial pressure of carbon dioxide: 60 to 70 mmHg)
Number of subjects: 50
Study 25751232 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 50
Study 23104320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (10 cc of 0.5% bupivacaine)
Number of subjects: 60
Study 23104320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 cc of normal saline)
Number of subjects: 60
Study 21325108 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g ethanol/kg body mass; n = 15)
Number of subjects: 30
Study 21325108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 30
Study 21325108 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g ethanol/kg body mass) during progressive LBNP
Number of subjects: 30
Study 19249634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine (10 mg twice daily; n=229)
Number of subjects: 301
Study 19249634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=72)
Number of subjects: 301
Study 19249634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine
Number of subjects: 301
Study 19249634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 16717292 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional sibling bone marrow transplantation (CBMT)
Number of subjects: 214
Study 16717292 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative donor bone marrow transplantation (ABMT)
Number of subjects: 214
Study 16717292 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 214
Study 16717292 — intervention group
Group type: EXPERIMENTAL
Intervention: CBMT
Number of subjects: 214
Study 16717292 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT
Number of subjects: 214
Study 16717292 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 214
Study 16600233 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms of peroxisome proliferator-activated receptor-gamma (Pro12Ala)
Number of subjects: 201
Study 16600233 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms of peroxisome proliferator-activated receptor-coactivator-1 (Gly482Ser)
Number of subjects: 201
Study 16600233 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index and reproductive hormones among various genotypic groups of PCOS
Number of subjects: 201
Study 16600233 — intervention group
Group type: COMPARATOR
Intervention: Control group (147 regularly cycling women)
Number of subjects: 201
Study 12707979 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitionally induced responses (V)
Number of subjects: 50
Study 10337295 — intervention group
Group type: EXPERIMENTAL
Intervention: Silux Plus
Number of subjects: 30
Study 10337295 — intervention group
Group type: EXPERIMENTAL
Intervention: Z100
Number of subjects: 30
Study 8588686 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms bd via Diskhaler (n = 121)
Number of subjects: 243
Study 2149648 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168
Study 2149648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168
Study 2149648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study 6775561 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (15 mg, intravenously)
Number of subjects: 6
Study 6775561 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (equivalent volume to naloxone)
Number of subjects: 6
Study 6775561 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg, intravenously)
Number of subjects: 6
Study 30710837 — intervention group
Group type: EXPERIMENTAL
Intervention: E + cPTH
Number of subjects: 48
Study 30710837 — intervention group
Group type: EXPERIMENTAL
Intervention: E + iPTH
Number of subjects: 48
Study 30710837 — intervention group
Group type: EXPERIMENTAL
Intervention: E
Number of subjects: 48
Study 30710837 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 28781171 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX plus SIRT
Number of subjects: 1103
Study 28781171 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX alone
Number of subjects: 1103
Study 26439944 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Number of subjects: 11
Study 24429275 — intervention group
Group type: EXPERIMENTAL
Intervention: RPL554 (0.009 mg/kg)
Number of subjects: 57
Study 24429275 — intervention group
Group type: EXPERIMENTAL
Intervention: RPL554 (0.018 mg/kg)
Number of subjects: 57
Study 21334654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 127
Study 21334654 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape-obturator
Number of subjects: 127
Study 19334042 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 20
Study 17284917 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste directly after erosion
Number of subjects: 5
Study 17284917 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste 2 hours after erosion
Number of subjects: 5
Study 17284917 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste before erosion
Number of subjects: 5
Study 17284917 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride toothpaste
Number of subjects: 5
Study 17284917 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride toothpaste or gel, and rinsing with a fluoride mouth rinse
Number of subjects: 5
Study 17284917 — intervention group
Group type: COMPARATOR
Intervention: Erosion only (no brushing)
Number of subjects: 5
Study 14754644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% coal tar lotion (Exorex)
Number of subjects: 324
Study 14754644 — intervention group
Group type: COMPARATOR
Intervention: 5% conventional coal tar lotion (Alphosyl)
Number of subjects: 324
Study 11359890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral intermetatarsal angle measurement in hallux limitus feet
Number of subjects: 60
Study 11359890 — intervention group
Group type: COMPARATOR
Intervention: Lateral intermetatarsal angle measurement in normal feet
Number of subjects: 60
Study 10322856 — intervention group
Group type: EXPERIMENTAL
Intervention: Yizhi capsule (YZC), 4 capsules each time, three times a day for two months
Number of subjects: 61
Study 10322856 — intervention group
Group type: EXPERIMENTAL
Intervention: Yizhi capsule (YZC)
Number of subjects: 61
Study 10322856 — intervention group
Group type: COMPARATOR
Intervention: Hydergine, 2 mg each time, three times a day for two months
Number of subjects: 61
Study 8490153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-spin-echo sequences (FSE)
Number of subjects: 20
Study 8490153 — intervention group
Group type: COMPARATOR
Intervention: Conventional spin-echo sequences (CSE)
Number of subjects: 20
Study 3449477 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (6,000 rad)
Number of subjects: 320
Study 3449477 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation therapy (5,000 rad)
Number of subjects: 320
Study 3449477 — intervention group
Group type: COMPARATOR
Intervention: Definitive radiation therapy (6,500‐7,000 rad)
Number of subjects: 320
Study 31344699 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physician-investigator driven enrollment method
Number of subjects: 1700
Study 31344699 — intervention group
Group type: COMPARATOR
Intervention: Self-consent
Number of subjects: 1700
Study 31344699 — intervention group
Group type: COMPARATOR
Intervention: LAR (Legally Authorized Representative) consent
Number of subjects: 1700
Study 31344699 — intervention group
Group type: COMPARATOR
Intervention: EFIC (Exception from Informed Consent)
Number of subjects: 1700
Study 28696380 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (25 g of MuscleTech 100% Whey)
Number of subjects: 12
Study 28696380 — intervention group
Group type: COMPARATOR
Intervention: Energy-matched placebo (CHO)
Number of subjects: 12
Study 28696380 — intervention group
Group type: COMPARATOR
Intervention: Rested control trial (no exercise, no supplement)
Number of subjects: 12
Study 24611590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat therapy combined with conventional therapy (twice a week Lokomat + three times 30 min conventional therapy)
Number of subjects: 30
Study 24611590 — intervention group
Group type: COMPARATOR
Intervention: Conventional assisted overground therapy only (3.5 h a week)
Number of subjects: 30
Study 23816026 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping drug-eluting stents (DESs)
Number of subjects: 31
Study 23816026 — intervention group
Group type: COMPARATOR
Intervention: Nonoverlapping drug-eluting stents (DESs)
Number of subjects: 31
Study 21441148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 14
Study 21441148 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 20104414 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based supported employment
Number of subjects: 301
Study 20104414 — intervention group
Group type: COMPARATOR
Intervention: Conventional vocational rehabilitation (standard care)
Number of subjects: 301
Study 16942557 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Histories (SH)
Number of subjects: 43
Study 16942557 — intervention group
Group type: COMPARATOR
Intervention: Unstructured History (USH)
Number of subjects: 43
Study 16942557 — intervention group
Group type: COMPARATOR
Intervention: Computer Database (CD)
Number of subjects: 43
Study 16942557 — intervention group
Group type: COMPARATOR
Intervention: Unstructured History (USH) and Structured Histories (SH)
Number of subjects: 43
Study 15225178 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 179
Study 15225178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day
Number of subjects: 179
Study 15225178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day
Number of subjects: 179
Study 15225178 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg/day
Number of subjects: 179
Study 12479619 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback balance training with the SMART Balance Master
Number of subjects: 41
Study 12479619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 9717526 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization
Number of subjects: 45
Study 9717526 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 45
Study 8122957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.1 mg/kg)
Number of subjects: 19
Study 8122957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 19
Study 8122957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2521863 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.01-0.05 mg initially, increased to 0.03-0.09 mg at 12 weeks)
Number of subjects: 26
Study 2521863 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502
Number of subjects: 26
Study 9883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisucccinate (150 mg/kg)
Number of subjects: 61
Study 9883 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl prednisolone sulfate (30 mg/kg)
Number of subjects: 61
Study 9883 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone sodium m sulfobenzoate (50 mg/kg)
Number of subjects: 61
Study 9883 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone sodium m sulfobenzoate (35 mg/kg)
Number of subjects: 61
Study 9883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (2 mg and 6 mg/kg)
Number of subjects: 61
Study 30094650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric N‐Bond Self‐Etch (TN; Ivoclar/Vivadent, Liechtenstein)
Number of subjects: 20
Study 30094650 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond 2 adhesive (SE; Kuraray Noritake Dental Inc, Japan)
Number of subjects: 20
Study 28530433 — intervention group
Group type: COMPARATOR
Intervention: Multilevel intervention aimed at improving mental health of PLH and their family members.
Number of subjects: 997
Study 28530433 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention for PLH.
Number of subjects: 997
Study 28530433 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention).
Number of subjects: 997
Study 25652389 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin deficiency (fasting C-peptide ≤0.15 nmol/l)
Number of subjects: 1401
Study 25652389 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of IAA autoantibodies or baseline insulin use
Number of subjects: 1401
Study 25652389 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD autoantibodies
Number of subjects: 1401
Study 25652389 — intervention group
Group type: EXPERIMENTAL
Intervention: IA2 autoantibodies
Number of subjects: 1401
Study 25652389 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnT8 autoantibodies
Number of subjects: 1401
Study 24400383 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine acridonacetate
Number of subjects: 100
Study 22021253 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach motivation (reward for navigating to correct locations)
Number of subjects: 0
Study 22021253 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance motivation (punishment for navigating to incorrect platforms)
Number of subjects: 0
Study 22021253 — intervention group
Group type: COMPARATOR
Intervention: Nonmotivated spatial learning
Number of subjects: 0
Study 22021253 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal during approach motivation
Number of subjects: 0
Study 22021253 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal across subjects
Number of subjects: 0
Study 22021253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-performing, highly aroused participants
Number of subjects: 0
Study 19222404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 63
Study 19222404 — intervention group
Group type: COMPARATOR
Intervention: Dim light therapy
Number of subjects: 63
Study 17117070 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐SSP z‐score maps
Number of subjects: 315
Study 17117070 — intervention group
Group type: COMPARATOR
Intervention: Standard transaxial section displays
Number of subjects: 315
Study 15097308 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of elemental iron given twice weekly for four months
Number of subjects: 0
Study 15097308 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of iron (not specified)
Number of subjects: 0
Study 10762511 — intervention group
Group type: EXPERIMENTAL
Intervention: Active p42MAPK expression in s‐IBM
Number of subjects: 7
Study 10762511 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot analysis of cell lysates
Number of subjects: 7
Study 10762511 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemistry using antibodies against phosphoepitopes
Number of subjects: 7
Study 10762511 — intervention group
Group type: COMPARATOR
Intervention: Disease controls (N=15)
Number of subjects: 7
Study 8614771 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 60
Study 8614771 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Treatment (SMT)
Number of subjects: 60
Study 8614771 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 60
Study 1466618 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) 0.1 mg/kg/day
Number of subjects: 20
Study 1466618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6704272 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine
Number of subjects: 3
Study 6704272 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine (0.5%)
Number of subjects: 3
Study 6704272 — intervention group
Group type: COMPARATOR
Intervention: Conventional i.v. morphine (control)
Number of subjects: 3
Study 31029230 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Number of subjects: 1085
Study 31029230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1085
Study 28809628 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder girdle muscles activation during wrist immobilization (group I, n=20, mean age 59.8 years)
Number of subjects: 40
Study 28809628 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (group II, n=20, mean age 61.3 years)
Number of subjects: 40
Study 24652598 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional treatment within a clinical pathway
Number of subjects: 0
Study 24652598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23244640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) - self-monitoring negative thoughts five times daily for 2 weeks
Number of subjects: 117
Study 23244640 — intervention group
Group type: COMPARATOR
Intervention: Non-EMA control group - did not self-monitor negative thoughts
Number of subjects: 117
Study 21795983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 95
Study 21795983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 19467543 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children (4- and 5-year-olds)
Number of subjects: 3
Study 19467543 — intervention group
Group type: COMPARATOR
Intervention: 3-year-olds
Number of subjects: 3
Study 16434656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg for 4 weeks, then maintained or titrated to 5 or 20 mg at weeks 4 and 8)
Number of subjects: 418
Study 16434656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 15726518 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (Ethyol; Medimmune Inc, Gaithersburg, MD) as a radiation protectant
Number of subjects: 0
Study 15726518 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11075309 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate (Citracal 250 mg + D)
Number of subjects: 25
Study 11075309 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (Os-Cal 500 mg + D)
Number of subjects: 25
Study 11075309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9211023 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 9211023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 0
Study 9211023 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 9211023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1543307 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position (45-degree angle)
Number of subjects: 19
Study 1543307 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19
Study 1543307 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 19
Study 3987645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1200 mg/day
Number of subjects: 8
Study 3987645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3359729 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 3359729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29603513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia risk score prediction model
Number of subjects: 27540
Study 28496022 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 64
Study 28496022 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan
Number of subjects: 64
Study 26111932 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT + TME
Number of subjects: 184
Study 26111932 — intervention group
Group type: COMPARATOR
Intervention: TME
Number of subjects: 184
Study 23870381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hep C nosode in 30c potency, once a week for four weeks
Number of subjects: 22
Study 23870381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21417535 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cognitive-behavioral therapy (CBT)
Number of subjects: 134
Study 21417535 — intervention group
Group type: COMPARATOR
Intervention: Delayed cognitive-behavioral therapy (CBT)
Number of subjects: 134
Study 18332407 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic illness management initiative involving joint formulation of comprehensive individual patient care plans
Number of subjects: 33
Study 18332407 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic illness management initiative
Number of subjects: 33
Study 16520665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib malate (SU11248) 50 mg after a high-fat, high-calorie meal
Number of subjects: 16
Study 16520665 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib malate (SU11248) 50 mg after a 10-h fast
Number of subjects: 16
Study 12920408 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/d
Number of subjects: 39